Skip to Main Content

Evolent Oncology Program Updates Effective April 1, 2027

Fidelis Care, in collaboration with Evolent, are implementing updates to the review and administration of oncology services to enhance member and provider experiences. These changes reflect a shared commitment to improving efficiency, reducing administrative burdens, and supporting timely, clinically appropriate care decisions.

What’s Changing

Denial Determinations for Oncology Services

Effective April 1, 2027, Evolent will issue denial determinations for oncology authorization requests that do not meet clinical criteria.

For requests received prior to April 1, 2027, Evolent will continue to issue Recommended Adverse Determinations (RADs) when clinical criteria are not met, and Fidelis Care will provide the final determination.

Please continue to submit grievances and appeals directly to Fidelis Care.

Pharmacy Benefit (Part D) Scope Update

Effective April 1, 2027, Evolent’s oncology review scope will be limited to medical-benefit (Part B) medications. All pharmacy-dispensed (Part D) drugs must be submitted directly to Fidelis Care, in accordance with plan guidelines.

Requests received prior to April 1, 2027 will be administered by Evolent under the current process.

For questions or additional information, please contact Fidelis Care provider services at 1-888-453-2534 (TTY 711).